Patents Assigned to Amgen
  • Combination therapy using a TNF binding protein for treating TNF-mediated diseases
    Patent number: 6306820
    Abstract: The invention relates to methods for treating or preventing acute and/or septic shock. The method comprises administering to patients in need thereof therapeutically effective amounts of a TNF binding protein and a Fas antigen. In a preferred embodiment, the TNF binding protein is sTNFR-I or sTNFR-II. The invention also relates to pharmaceutical compositions containing a TNF binding protein and a Fas antigen useful in such methods.
    Type: Grant
    Filed: June 4, 1999
    Date of Patent: October 23, 2001
    Assignee: Amgen Inc.
    Inventors: Alison M. Bendele, Regina M. Sennello, Carl K. Edwards III
  • Agouti and agouti-related peptide analogs
    Patent number: 6303749
    Abstract: The present invention provides peptides related to agouti signaling protein and agouti related protein which are useful in modulating the activity of the melanocortin 3 and melanocortin 4 receptors. Also provided are methods of preparing the peptides, as well as nucleic acid molecules encoding the peptides.
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: October 16, 2001
    Assignee: Amgen Inc.
    Inventor: Mark Anthony Jarosinski
  • Antibodies against analogs of brain-derived neurotrophic factor
    Publication number: 20010027179
    Abstract: The in vivo circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3 and BDNF, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.
    Type: Application
    Filed: December 19, 2000
    Publication date: October 4, 2001
    Applicant: Amgen Inc.
    Inventors: Thomas Charles Boone, Ellen Ngoi Yin Cheung, Susan Irene Hershenson, John David Young
  • TNF receptors, TNF binding proteins and DNAs coding for them
    Patent number: 6294352
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequence can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: February 1, 1995
    Date of Patent: September 25, 2001
    Assignee: Amgen Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • Composition and method for treating inflammatory diseases
    Patent number: 6294170
    Abstract: A protein which exhibits a therapeutic effect on inflammation and is useful for treating IL-1-mediated inflammatory diseases, particularly diseases of the joint.
    Type: Grant
    Filed: August 7, 1998
    Date of Patent: September 25, 2001
    Assignee: Amgen Inc.
    Inventors: Thomas C. Boone, Susan Hershenson, Michael P. Bevilacqua, David S. Collins
  • Mammalian cell cycle protein
    Patent number: 6291642
    Abstract: A novel mammalian cell cycle protein, p55CDC, DNA sequences encoding p55CDC, and a method for producing the protein are described. Also described are methods for detecting p55CDC and methods for modulating cell division by compounds which control the level or activity of p55CDC or p55CDC-associated protein complexes.
    Type: Grant
    Filed: December 11, 1997
    Date of Patent: September 18, 2001
    Assignees: Amgen Inc., The Regents of the University of California
    Inventor: Jasminder Weinstein
  • Recombinant methods for production of serine protease inhibitors and DNA sequences
    Patent number: 6291662
    Abstract: A synthetic DNA sequence and its genetic equivalents are disclosed which sequences are capable, when used in a recombinant DNA method, of directing production of a serine protease inibitor protein. Recombinant DNA methods for the production of serine protease inhibitor proteins are also disclosed. These methods incorporate either the synthetic DNA sequence of the present invention or natural DNA sequences isolated from human cDNA or genomic libraries.
    Type: Grant
    Filed: September 22, 1998
    Date of Patent: September 18, 2001
    Assignee: Amgen Inc.
    Inventors: Pradip K. Bandyopadhyay, Stephen P. Eisenberg, Gary L. Stetler, Robert C. Thompson
  • Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
    Patent number: 6291450
    Abstract: Selected novel carboxylic acid substituted heterocycle compounds are effective for prophylaxis and treatment of inflammation, tissue degradation, cancer, fibrosis and related diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of inflamation, tissue degradation and related diseases. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: September 18, 2001
    Assignee: Amgen Inc.
    Inventors: Kevin Koch, Andreas Termin, John A. Josey
  • Stem cell factor formulations and methods
    Patent number: 6288030
    Abstract: The present invention relates to lyophilized formulations of Stem Cell Factor (SCF) with increased stability. The formulations of lyophilized SCF include amino acid buffers and sucrose. Methods of producing said formulations are also disclosed in the specification.
    Type: Grant
    Filed: December 22, 1993
    Date of Patent: September 11, 2001
    Assignee: Amgen Inc.
    Inventor: Susan I. Hershenson
  • Osteoprotegerin
    Patent number: 6288032
    Abstract: The present invention discloses a novel secreted polypeptide, termed Osteoprotegerin, which is a member of the tumor necrosis factor receptor super family and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding Osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind Osteoprotegerin, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.
    Type: Grant
    Filed: February 6, 1997
    Date of Patent: September 11, 2001
    Assignee: Amgen Inc.
    Inventors: William J. Boyle, David L. Lacey, Frank J. Calzone, Ming-Shi Chang
  • Osteoprotegerin
    Patent number: 6284728
    Abstract: The present invention discloses a novel secreted polypeptide, termed Osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding Osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind Osteoprotegerin, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.
    Type: Grant
    Filed: February 6, 1997
    Date of Patent: September 4, 2001
    Assignee: Amgen Inc.
    Inventors: William J. Boyle, David L. Lacey, Frank J. Calzone, Ming-Shi Chang
  • Nucleic acids encoding osteoprotegerin
    Patent number: 6284485
    Abstract: The present invention discloses a novel secreted polypeptide, termed Osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding Osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind Osteoprotegerin, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.
    Type: Grant
    Filed: February 6, 1997
    Date of Patent: September 4, 2001
    Assignee: Amgen Inc.
    Inventors: William J. Boyle, David L. Lacey, Frank J. Calzone, Ming-Shi Chang
  • Osteoprotegerin
    Patent number: 6284740
    Abstract: The present invention discloses a novel secreted polypeptide, termed Osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding Osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind Osteoprotegerin, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.
    Type: Grant
    Filed: November 18, 1997
    Date of Patent: September 4, 2001
    Assignee: Amgen Inc.
    Inventors: William J. Boyle, David L. Lacey, Frank J. Calzone, Ming-Shi Chang
  • G-CSF analog compositions and methods
    Publication number: 20010016191
    Abstract: The present invention relates to granulocyte colony-stimulating factor (“G-CSF”) hybrid molecules which retain the internal core helices of G-CSF. Also provided are pharmaceutical compositions containing hybrid molecules.
    Type: Application
    Filed: January 3, 2001
    Publication date: August 23, 2001
    Applicant: AMGEN INC.
    Inventor: Timothy D. Osslund
  • Method for preventing and treating hearing loss using a neurturin protein product
    Patent number: 6274554
    Abstract: The present invention relates generally to methods for preventing and/or treating injury or degeneration of cochlear hair cells and spiral ganglion neurons by administering a neurturin neurotrophic factor protein product. The invention relates more specifically to methods for treating sensorineural hearing loss.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: August 14, 2001
    Assignee: Amgen Inc.
    Inventors: Ella Magal, John M. Delaney
  • Analogs of NT-3
    Patent number: 6271364
    Abstract: The in vivo circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: August 7, 2001
    Assignee: Amgen Inc.
    Inventors: Ellen Ngoi Yin Cheung, Thomas Charles Boone, Susan Irene Hershenson, John David Young
  • TNF Receptors, TNF binding proteins and DNAs coding for them
    Patent number: 6271346
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 7, 2001
    Assignee: Amgen Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • Tissue specific transgene expression
    Patent number: 6268212
    Abstract: This invention provides a mammal with enhanced liver expression of a transgene. Also provided are 1) a nucleic acid sequence useful in enhancing liver specific expression of a transgene, and 2) a vector containing this nucleic acid sequence.
    Type: Grant
    Filed: March 31, 1994
    Date of Patent: July 31, 2001
    Assignee: Amgen Inc.
    Inventor: William Scott Simonet
  • Fibronolytically active polypeptide
    Patent number: 6261820
    Abstract: A fibrinolytically active metalloproteinase polypeptide (called “novel acting thrombolytic”) which is useful for blood clot lysis in vivo and methods and materials for its production by recombinant expression are described.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: July 17, 2001
    Assignee: Amgen Inc.
    Inventors: Thomas C. Boone, Huimin Li, Michael B. Mann
  • G-CSF hybrid molecules and pharmaceutical compositions
    Patent number: 6261550
    Abstract: The present invention relates to granulocyte colony-stimulating factor (“G-CSF”) analogs and compositions containing such analogs which retain the three-dimensional structure of the internal core of the four alpha helical bundle of G-CSF. In another aspect, such G-CSF analogs can also be attached with biologically active proteins to form hybrid molecules and still retain G-CSF structural integrity. Also provided are methods for determining and preparing analog or hybrid molecules and modifications.
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: July 17, 2001
    Assignee: Amgen Inc.
    Inventor: Timothy David Osslund